ArticleMethods in molecular biology (Clifton, N.J.)2026
Anti-platelet Factor 4/Heparin Antibody Production in a Mouse Immunization Model.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heparin-induced thrombocytopenia (HIT) is the most prevalent form of drug-induced, immune-mediated thrombocytopenia. It involves the production of antibodies that target platelet factor 4 (PF4) in complex with heparin, leading to platelet activation. The pathogenesis of HIT is not fully understood, primarily due to the limitations of studying human patients. To bridge this gap and gain a deeper understanding of the mechanisms behind HIT antibody generation, researchers developed a murine model using immunization with mouse PF4 (mPF4)/heparin complexes. Here, we provide a detailed methodology for inducing mPF4/heparin antibodies in C57BL/6 mice and validating the immunization process. Through these techniques, we identified the critical subset of B cells responsible for producing mPF4/heparin-specific antibodies, as well as other immune cells essential for regulating this production. This immunization-based mouse model of HIT is a valuable tool for studying the immunopathogenesis of the condition.
Indexed as
Identifiers
42681409What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.